In this review:
Hormone therapy and postoperative RT for recurrent prostate cancer
Predicting prostate cancer in PI-RADS 1-2 lesions
SBRT vs high dose rate brachytherapy
177Lu-PSMA-617 for oligometastatic HSPC
Nomogram-based classification of response to metastasis-directed SBRT
SBRT to the prostate with focal boost
mpMRI + PSMA PET/CT for diagnosis after biochemical recurrence
Active surveillance for patients aged ≥75 years
18F-Fluciclovine-PSMA-11-guided salvage radiotherapy dose escalation
Fluorescence confocal microscopy for surgical margin assessment
Please login below to download this issue (PDF)